{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:51:25Z","timestamp":1790801485353,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":1194,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects up to one in five children and millions of adults in developed countries. Clinically, AD skin lesions manifest as subacute and\/or chronic lichenified eczematous plaques, which are often intensely pruritic and prone to secondary bacterial and viral infections. Despite the emergence of novel therapeutic agents, treatment options and outcomes for AD remain suboptimal. An improved understanding of AD pathogenesis may help improve patient outcomes. Dysregulated Th2-polarized skin inflammation and impaired skin barrier function interact to drive AD pathogenesis; however, much remains to be understood about the molecular mechanisms underlying this interplay. The current study used published clinical trial datasets to define a skin-related AD gene signature. This meta-analysis revealed significant reductions in IL1F7 transcripts (encodes IL-37) in AD patient samples. Reduced IL1F7 correlated with lower transcripts for key skin barrier function genes in the epidermal differentiation complex. Immunohistochemical analysis of normal (healthy) human skin specimens and an in vitro three-dimensional human skin model localized IL-37 protein to the epidermis. In comparison with normal human skin, IL-37 levels were decreased in AD patient skin. Addition of Th2 cytokines to the aforementioned in vitro three-dimensional skin model recapitulates key aspects of AD skin and was sufficient to reduce epidermal IL-37 levels. Image analysis also indicated close relationship between epidermal IL-37 and skin epidermal differentiation complex proteins. These findings suggest IL-37 is intimately linked to normal keratinocyte differentiation and barrier function and implicates IL-37 as a potential biomarker and therapeutic target for AD.<\/jats:p>","DOI":"10.4049\/immunohorizons.2100055","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T16:20:50Z","timestamp":1635265250000},"page":"830-843","source":"Crossref","is-referenced-by-count":17,"title":["Transcriptomic Analysis of Healthy and Atopic Dermatitis Samples Reveals the Role of IL-37 in Human Skin"],"prefix":"10.1093","volume":"5","author":[{"given":"Jiajun","family":"Zhou","sequence":"first","affiliation":[{"name":"Lilly Research Laboratory, Eli Lilly and Company , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Gemperline","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratory, Eli Lilly and Company , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Turner","sequence":"additional","affiliation":[{"name":"School of Medicine, Indiana University , Indianapolis, IN"},{"name":"Richard L. Roudebush Veterans Affairs Medical Center , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-4306","authenticated-orcid":false,"given":"Jonathan","family":"Oldach","sequence":"additional","affiliation":[{"name":"MatTek Life Sciences , Ashland, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Molignano","sequence":"additional","affiliation":[{"name":"MatTek Life Sciences , Ashland, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-2157","authenticated-orcid":false,"given":"Jonathan T","family":"Sims","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratory, Eli Lilly and Company , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R","family":"Stayrook","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratory, Eli Lilly and Company , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"2025010703495026500_r1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2018.03.017","article-title":"Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis.","volume":"79","author":"R\u00f8nnstad","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"2025010703495026500_r2","first-page":"108","article-title":"Pathophysiology of atopic dermatitis and psoriasis: implications for management in children.","volume":"6","author":"Chovatiya","year":"2019","journal-title":"Children (Basel)."},{"key":"2025010703495026500_r3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study.","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"2025010703495026500_r4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamadermatol.2018.1572","article-title":"Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis.","volume":"154","author":"Simpson","year":"2018","journal-title":"JAMA Dermatol."},{"key":"2025010703495026500_r5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000451083","article-title":"Targeting the T helper 2 inflammatory axis in atopic dermatitis.","volume":"171","author":"Moreno","year":"2016","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"6","key":"2025010703495026500_r6","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.jaci.2003.09.032","article-title":"Immune mechanisms leading to atopic dermatitis.","volume":"112","author":"Novak","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025010703495026500_r7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ad.2013.10.019","article-title":"The role of filaggrin in the skin barrier and disease development.","volume":"106","author":"Armengot-Carbo","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"2025010703495026500_r8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41232-017-0044-7","article-title":"The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus.","volume":"37","author":"Rerknimitr","year":"2017","journal-title":"Inflamm. Regen."},{"key":"2025010703495026500_r9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2332\/allergolint.10-RAI-0270","article-title":"Filaggrin gene defects and the risk of developing allergic disorders.","volume":"60","author":"Osawa","year":"2011","journal-title":"Allergol. Int."},{"key":"2025010703495026500_r10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","article-title":"Significance of skin barrier dysfunction in atopic dermatitis.","volume":"10","author":"Kim","year":"2018","journal-title":"Allergy Asthma Immunol. Res."},{"key":"2025010703495026500_r11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clim.2007.11.006","article-title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6.","volume":"126","author":"Kim","year":"2008","journal-title":"Clin. Immunol."},{"key":"2025010703495026500_r12","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/jid.2011.24","article-title":"TNF-\u03b1 downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-\u03b1 antagonists to improve skin barrier. [Published erratum appears in 2011 J. Invest. Dermatol. 131: 1388.]","volume":"131","author":"Kim","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"2025010703495026500_r13","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1242\/jcs.033969","article-title":"Filaggrin in the frontline: role in skin barrier function and disease.","volume":"122","author":"Sandilands","year":"2009","journal-title":"J. Cell Sci."},{"key":"2025010703495026500_r14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jaci.2009.07.034","article-title":"Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum.","volume":"124","author":"Gao","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025010703495026500_r15","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/sj.jid.5700739","article-title":"Filaggrin mutations in children with severe atopic dermatitis.","volume":"127","author":"Morar","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"2025010703495026500_r16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jaci.2017.01.039","article-title":"Proteomic analysis of filaggrin deficiency identifies molecular signatures characteristic of atopic eczema.","volume":"140","author":"Elias","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025010703495026500_r17","first-page":"4711","article-title":"Interleukin-37: a crucial cytokine with multiple roles in disease and potentially clinical therapy.","volume":"15","author":"Wang","year":"2018","journal-title":"Oncol. Lett."},{"key":"2025010703495026500_r18","doi-asserted-by":"crossref","first-page":"eaaj1548","DOI":"10.1126\/sciimmunol.aaj1548","article-title":"Homodimerization attenuates the anti-inflammatory activity of interleukin-37.","volume":"2","author":"Ellisdon","year":"2017","journal-title":"Sci. Immunol."},{"key":"2025010703495026500_r19","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/ni968","article-title":"SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling.","volume":"4","author":"Wald","year":"2003","journal-title":"Nat. Immunol."},{"key":"2025010703495026500_r20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.it.2009.06.001","article-title":"TIR8\/SIGIRR: an IL-1R\/TLR family member with regulatory functions in inflammation and T cell polarization.","volume":"30","author":"Garlanda","year":"2009","journal-title":"Trends Immunol."},{"key":"2025010703495026500_r21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jclinepi.2014.03.012","article-title":"False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies.","volume":"67","author":"Glickman","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"2025010703495026500_r22","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.tiv.2009.07.021","article-title":"Microvesicating effects of sulfur mustard on an in vitro human skin model.","volume":"23","author":"Hayden","year":"2009","journal-title":"Toxicol. In Vitro."},{"key":"2025010703495026500_r23","doi-asserted-by":"crossref","first-page":"109705","DOI":"10.1016\/j.biopha.2019.109705","article-title":"The role of IL-37 in skin and connective tissue diseases.","volume":"122","author":"Pan","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"2025010703495026500_r24","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4049\/immunohorizons.2000083","article-title":"IL-37 expression is downregulated in lesional psoriasis skin.","volume":"4","author":"R\u00f8nholt","year":"2020","journal-title":"ImmunoHorizons."},{"key":"2025010703495026500_r25","doi-asserted-by":"crossref","first-page":"17446","DOI":"10.1038\/s41598-017-17782-4","article-title":"Epidermal cornification is preceded by the expression of a keratinocyte-specific set of pyroptosis-related genes.","volume":"7","author":"Lachner","year":"2017","journal-title":"Sci. Rep."}],"container-title":["ImmunoHorizons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/5\/10\/830\/61339725\/ih2100055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/5\/10\/830\/61339725\/ih2100055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T03:53:50Z","timestamp":1736222030000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article\/5\/10\/830\/7820232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.4049\/immunohorizons.2100055","relation":{},"ISSN":["2573-7732"],"issn-type":[{"value":"2573-7732","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10]]},"published":{"date-parts":[[2021,10,1]]}}}